A Coiled-Coil Oligomerization Domain of Bcr Is Essential for the Transforming Function of Bcr-Abl Oncoproteins

John R. McWhirter, Debora L. Galasso, Jean Y. J. Wang

Molecular and Cellular Biology · 1993 · 115 citations · 30 references

Concepts

TL;DR

Philadelphia chromosome‑positive leukemias arise from a fusion of the c‑abl proto‑oncogene with the bcr gene, producing chimeric Bcr‑Abl proteins that require Bcr domains 1 and 2 for transforming activity, with domain 1 predicted to be a coiled‑coil oligomerization domain. The fusion of Bcr sequences activates Abl’s tyrosine kinase, actin‑binding, and transforming functions. Domain 1 of Bcr forms a homotetramer, and its tetramerization is essential for activating Abl’s tyrosine kinase and actin‑binding functions; disrupting the coiled‑coil abolishes Bcr‑Abl’s transforming ability, indicating that Bcr‑Abl oligomers are the active entities in transformation.

Abstract

In Philadelphia chromosome-positive human leukemias, the c-abl proto-oncogene on chromosome 9 becomes fused to the bcr gene on chromosome 22, and chimeric Bcr-Abl proteins are produced. The fused Bcr sequences activate the tyrosine kinase, actin-binding, and transforming functions of Abl. Activation of the Abl transforming function has been shown to require two distinct domains of Bcr: domain 1 (Bcr amino acids 1 to 63) and domain 2 (Bcr amino acids 176 to 242). The amino acid sequence of domain 1 indicates that it may be a coiled-coil oligomerization domain. We show here that domain 1 of Bcr forms a homotetramer. Tetramerization of Bcr-Abl through Bcr domain 1 correlates with activation of the tyrosine kinase and F-actin-binding functions of Abl. Disruption of the coiled coil by insertional mutagenesis inactivates the oligomerization function as well as the ability of Bcr-Abl to transform Rat-1 fibroblasts or to abrogate interleukin-3 dependence in lymphoid cells. These results strongly suggest that Bcr-Abl oligomers are the active entities in transformation.

References

30